OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
27 sep 2007 - 07:21
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus in-licences diabetes product candidate
Bericht
OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO), the drug delivery and development company, announces today that it has acquired exclusive worldwide rights to develop and commercialise a family of compounds, including a GLP-1 agonist product candidate for the treatment of type 2 diabetes from Canadian biopharmaceutical company Theratechnologies (TSX: TH). The product candidate has been selected by OctoPlus for development into a long-acting controlled release formulation that may substantially reduce the required dosing frequency in diabetes therapy, compared to current products on the market or in development, and with a potentially better tolerability profile. OctoPlus has initiated pre-clinical development of this product.
Datum laatste update: 20 december 2025